SUNPHARMA

Sun Pharmaceutical Industries Limited · NSE · INE044A01036 · F&O · lot 350 · 272 sessions on record

₹1,801.00▼ −15.60 · −0.9%from ₹1,816.60 the session before · 1 Oct 2026 close · NSE end of day

Open: ₹1,815.00
High: ₹1,828.70
Low: ₹1,792.60
Day's range: ₹362.0% of the previous close
VWAP: ₹1,807.36close −0.35% from it
Volume, shares: 23 L1.51× the 20-session average
Turnover, ₹ crore: 420
Trades: 89,00026 shares per trade
Previous close: ₹1,816.60−15.60 to the close
Price band, next session: ₹1,620.90 – ₹1,981.1010% either side of the close · dynamic, widened in 5% steps when hit

Day range23% of the way up

₹1,792.60₹1,828.70

52-week range47% of the way up

₹1,583.70 29 Jan₹2,046.90 31 Jul

−12% from the high · +14% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days

short build-up

futures read

price −0.9% · OI +2.5%

+11.90

futures premium, ₹

+0.7% to spot ₹1,801.00

0.78

puts per call, by OI

by volume 0.75

1,840

max pain

+2.2% from the close

▲ +2.5%

futures OI on the day

+1,100 lots · 47,000 open

Short build-up into a 26-day expiry: futures OI +2.5% on a −0.9% day, the most call OI sits at 1,920, the most put OI at 1,780, max pain 1,840.

Futures and options

1 Oct close · lot 350 · NSE end of day

SUNPHARMA futures closed at ₹1,812.90, +0.7% to spot, with 93% of open interest in the 27 Oct contract, and the 1,800 straddle prices a move of about ±3.9% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹1,801.00

Futures by expiry, basis against the spot close ₹1,801.00
Expiry	Close ₹	Basis ₹ · %	Annualised %	OI lots · on the day	Share of OI %	Contracts traded
27 Oct26 days	₹1,812.90	+11.90+0.7%	+9.3%	44,000▲ +2.3% · +1,000 lots	93	3,900
23 Nov53 days	₹1,821.60	+20.60+1.1%	+7.9%	3,100▲ +2.5% · +76 lots	6.6	190
29 Dec89 days	₹1,832.70	+31.70+1.8%	+7.2%	480.0% · +48 lots	0.10	64

6.7% of futures OI sits beyond the 27 Oct contract · 40 of 57 listed contracts traded · 29,000 option contracts changed hands

Options27 Oct expiry · 26 days

The 1,800 straddle closed at ₹70.10 (call 41.55 + put 28.55), pricing a move of about ±3.9% by the 27 Oct expiry. In the last 253 windows of 19 sessions, SUNPHARMA moved more than that 131 times.

Call OI, lots: 11,00037 L shares
Put OI, lots: 8,40029 L shares
Puts per call, by OI: 0.78by volume 0.75
Max pain: 1,840+2.2% from the close
Contracts traded: 40 of 57listed for this expiry

Open interest by strike, lotstop three strikes each side

Calls

Strike

Puts

2,000

1,920

1,500

1,900

1,700

1,860

930

1,780

1,600

1,660

1,200

Open interest added on the day, lotsthree largest additions each side

Calls

Strike

Puts

+480

1,920

+310

1,860

+240

1,820

+180

1,800

+280

1,700

+170

Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

272 sessions on file · from 28 Aug

SUNPHARMA close
Nifty 50, rebased
long build-up · price up, OI up
short build-up · price down, OI up
short covering · price up, OI down
long unwinding · price down, OI down

Session read · latest close: 1 Oct 2026
Close ₹ · day %: ₹1,801.00▼ −0.9% on the previous close
Against Nifty 50: Nifty −0.9%0.0 pp difference on the day
Futures OI, lots: 47,000+1,100 lots · +2.5% on the day
The day's build-up: short build-upprice −0.9% · OI +2.5%
Against the averages: below 20 · below 5020-session ₹1,857.90 (−3.1%) · 50-session ₹1,906.29 (−5.5%)
Volume: 1.51×the previous 20 sessions · 23 L shares
Extremes on the day: none

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 8 bulletins, SUNPHARMA closed higher five sessions later in 4 of 8.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
Bulletin	Day of the news	1 session later	5 sessions later	Futures OI on the day
26 JulSun Pharma's $9.4 billion Organon acquisition approved	▲ +1.7%Nifty +1.0% · +0.7 pp	▲ +1.8%Nifty +0.9% · +0.9 pp	▲ +1.1%Nifty +4.2% · −3.1 pp	▲ +6.7%long build-up
24 JulOrganon shareholders approve Sun Pharma's $11.75 billion acquisition	▲ +1.7%Nifty +1.0% · +0.7 pp	▲ +1.8%Nifty +0.9% · +0.9 pp	▲ +1.1%Nifty +4.2% · −3.1 pp	▲ +6.7%long build-up
15 JulSun Pharma Q1 earnings call set for July 31 after profit surge	▲ +0.5%Nifty +0.1% · +0.3 pp	▲ +0.4%Nifty +0.1% · +0.3 pp	0.0%Nifty −0.2% · +0.3 pp	▼ −1.1%short covering
11 JulSun Pharma to review Q1 FY27 results on July 31	▼ −0.7%Nifty 0.0% · −0.8 pp	▲ +0.4%Nifty −0.6% · +1.0 pp	▲ +1.1%Nifty +0.1% · +0.9 pp	▼ −0.5%long unwinding
25 MaySun Pharma Q4 net profit rises 26.2% to ₹27,140 million	0.0%Nifty −0.5% · +0.5 pp	▲ +0.2%Nifty −0.5% · +0.7 pp	▼ −2.8%Nifty −2.6% · −0.2 pp	▲ +0.2%long build-up
23 MaySun Pharma Q4 profit rises 26% YoY to ₹2,714 crore	▼ −0.2%Nifty +1.3% · −1.5 pp	▼ −0.2%Nifty +0.8% · −1.0 pp	▼ −3.0%Nifty −1.0% · −2.0 pp	▼ −4.5%long unwinding
20 MaySensex drops 600 points amid geopolitical uncertainty	▲ +0.6%Nifty 0.0% · +0.6 pp	▼ −1.9%Nifty +0.3% · −2.1 pp	▼ −4.3%Nifty −0.5% · −3.8 pp	▲ +1.2%long build-up
20 MayIndian firms announce $20.5 billion investment in US	▲ +0.6%Nifty 0.0% · +0.6 pp	▼ −1.9%Nifty +0.3% · −2.1 pp	▼ −4.3%Nifty −0.5% · −3.8 pp	▲ +1.2%long build-up

8 of 22 bulletins

Quarterly results

consolidated · latest filed 31 Jul, 06:24 pm IST · NSE filings

Revenue ₹15,300 cr, +10% on a year earlier; profit ₹2,901 cr, +27% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session

Quarterly results of SUNPHARMA on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹	Market on the day
Jun 2026filed 31 Jul	₹15,300 cr	▲ +10%	₹2,901 cr	▲ +27%	12.10	▼ −1.4%Nifty +1.6% · −3.0 pp
Mar 2026filed 22 May · audited	₹14,612 cr	▲ +13%	₹2,710 cr	▲ +26%	11.30	▼ −0.2%Nifty +1.3% · −1.5 pp
Dec 2025filed 31 Jan	₹15,521 cr	▲ +13%	₹3,381 cr	▲ +16%	14.00	▲ +0.9%Nifty −2.0% · +2.9 pp
Sept 2025filed 5 Nov	₹14,478 cr	▲ +8.9%	₹3,125 cr	▲ +2.9%	13.00	▼ −0.2%Nifty −0.3% · +0.1 pp
Jun 2025filed 31 Jul	₹13,851 cr	▲ +9.5%	₹2,293 cr	▼ −20%	9.50	▼ −4.5%Nifty −0.8% · −3.7 pp
Mar 2025filed 22 May · audited	₹12,959 cr	▲ +8.1%	₹2,154 cr	▼ −19%	9.00	▼ −2.0%Nifty +1.0% · −3.0 pp
Dec 2024filed 31 Jan	₹13,675 cr	▲ +10%	₹2,913 cr	▲ +14%	12.10	▼ −0.1%Nifty −0.1% · 0.0 pp
Sept 2024filed 28 Oct	₹13,291 cr	▲ +9.0%	₹3,037 cr	▲ +27%	12.70	▼ −1.6%Nifty +0.5% · −2.2 pp

By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years

Financial-year results of SUNPHARMA on the consolidated basis, summed from the quarters filed
Year	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹
FY26to Mar 2026	₹58,462 cr	▲ +11%	₹11,509 cr	▲ +5.0%	47.80
FY25to Mar 2025	₹52,578 cr	▲ +8.4%	₹10,965 cr	▲ +14%	45.60
FY24to Mar 2024	₹48,497 cr	—	₹9,610 cr	—	39.90

Fundamentals

consolidated · filings to Jun 2026 · close ₹1,801.00 on 1 Oct

SUNPHARMA trades at 36 times trailing earnings against 38 for its industry, 5.2 times book value, revenue +11% over twelve months, a 1.8% dividend yield, market cap ₹4,30,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing

Market cap: ₹4,30,000 cron 1 Oct · free float ₹2,00,000 cr
Price to earnings: 36consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS: ₹50.40diluted · consolidated · four quarters to Jun 2026
Price to book: 5.2consolidated · balance sheet to Mar 2026
Book value a share: ₹349.60consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity: 0.05borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity: 16%trailing profit over average equity · consolidated
Dividend yield: 1.8%₹32.00 a share in 365 days
Face value: ₹1a share
Shares outstanding: 240 cron 1 Oct

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: ₹59,911 crfour quarters to Jun 2026
Revenue growth, 12 months: ▲ +11%against the twelve months before
Revenue 2-year CAGR: ▲ +10%trailing twelve months against the twelve months 2 years earlier · consolidated
Profit, trailing 12 months: ₹12,117 crfour quarters to Jun 2026
Profit growth, 12 months: ▲ +17%against the twelve months before
Profit 2-year CAGR: ▲ +7.6%trailing twelve months against the twelve months 2 years earlier · consolidated

PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks

Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
Stock	Market cap ₹	P/E	P/B	Close ₹
SUNPHARMASun Pharmaceutical Industries Limited	4,30,000 cron 1 Oct	36consolidated	5.2	₹1,801.00
DIVISLABDivi's Laboratories Limited	2,50,000 cron 1 Oct	52consolidated	15	₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited	1,80,000 cron 1 Oct	76consolidated	10	₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited	1,10,000 cron 1 Oct	26consolidated	3.9	₹1,145.70
CIPLACipla Limited	1,10,000 cron 1 Oct	32consolidated	3.1	₹1,344.00
LAURUSLABSLaurus Labs Limited	1,10,000 cron 1 Oct	85consolidated	20	₹1,984.00
MANKINDMankind Pharma Limited	1,00,000 cron 1 Oct	51consolidated	6.3	₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited	1,00,000 cron 1 Oct	31consolidated	2.6	₹1,206.20
AUROPHARMAAurobindo Pharma Limited	96,000 cron 1 Oct	26consolidated	2.5	₹1,676.80
LUPINLupin Limited	93,000 cron 1 Oct	17consolidated	4.1	₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited	66,000 cron 1 Oct	37consolidated	6.3	₹2,331.00
ALKEMAlkem Laboratories Limited	62,000 cron 1 Oct	29consolidated	4.3	₹5,220.00
BIOCONBiocon Limited	60,000 cron 1 Oct	110consolidated	1.6	₹370.70
ABBOTINDIAAbbott India Limited	57,000 cron 1 Oct	—	—	₹26,840.00
IPCALABIPCA Laboratories Limited	49,000 cron 1 Oct	—	5.2	₹1,943.20
GLANDGland Pharma Limited	47,000 cron 1 Oct	—	4.6	₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited	47,000 cron 1 Oct	—	21	₹2,771.10
AJANTPHARMAjanta Pharma Limited	45,000 cron 1 Oct	—	9.9	₹3,581.00
EMCUREEmcure Pharmaceuticals Limited	37,000 cron 1 Oct	—	7.4	₹1,944.60
WOCKPHARMAWockhardt Limited	34,000 cron 1 Oct	—	6.4	₹2,083.90
SAILIFESai Life Sciences Limited	33,000 cron 1 Oct	—	13	₹1,541.20
NEULANDLABNeuland Laboratories Limited	28,000 cron 1 Oct	—	15	₹21,505.00
RUBICONRubicon Research Limited	27,000 cron 1 Oct	—	21	₹1,630.90
PPLPHARMAPiramal Pharma Limited	26,000 cron 1 Oct	—	3.2	₹197.95
ACUTAASAcutaas Chemicals Limited	26,000 cron 1 Oct	—	15	₹3,196.50
SHILPAMEDShilpa Medicare Limited	21,000 cron 1 Oct	—	8.0	₹1,064.10
GRANULESGranules India Limited	20,000 cron 1 Oct	—	4.0	₹821.75
CAPLIPOINTCaplin Point Laboratories Limited	20,000 cron 1 Oct	—	5.5	₹2,631.90
PFIZERPfizer Limited	18,000 cron 1 Oct	—	4.2	₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited	17,000 cron 1 Oct	—	3.0	₹1,508.00
COHANCECohance Lifesciences Limited	17,000 cron 1 Oct	—	4.3	₹451.30
ALIVUSAlivus Life Sciences Limited	17,000 cron 1 Oct	—	5.1	₹1,374.20
ERISEris Lifesciences Limited	16,000 cron 1 Oct	—	4.2	₹1,189.80
NATCOPHARMNatco Pharma Limited	16,000 cron 1 Oct	—	1.8	₹821.30
APLLTDAlembic Pharmaceuticals Limited	16,000 cron 1 Oct	—	2.8	₹815.25
JUBLPHARMAJubilant Pharmova Limited	16,000 cron 1 Oct	—	2.2	₹999.30
ASTRAZENAstraZeneca Pharma India Limited	15,000 cron 1 Oct	—	17	₹6,031.00
MARKSANSMarksans Pharma Limited	15,000 cron 1 Oct	—	4.8	₹325.60
CONCORDBIOConcord Biotech Limited	14,000 cron 1 Oct	—	7.1	₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited	13,000 cron 1 Oct	—	3.8	₹813.10
CORONACORONA Remedies Limited	12,000 cron 1 Oct	—	17	₹2,029.40
BLUEJETBlue Jet Healthcare Limited	10,000 cron 1 Oct	—	7.5	₹541.80
VIYASHViyash Scientific Limited	10,000 cron 1 Oct	—	3.3	₹231.75
STARStrides Pharma Science Limited	10,000 cron 1 Oct	—	3.2	₹1,084.80
PGHLProcter & Gamble Health Limited	8,900 cron 1 Oct	—	17	₹5,360.00
AARTIPHARMAarti Pharmalabs Limited	8,800 cron 1 Oct	—	4.1	₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited	8,700 cron 1 Oct	—	25	₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited	7,700 cron 1 Oct	—	—	₹1,198.00
SUPRIYASupriya Lifescience Limited	7,500 cron 1 Oct	—	6.3	₹931.00
MOREPENLABMorepen Laboratories Limited	7,300 cron 1 Oct	—	5.9	₹133.70
SANOFISanofi India Limited	7,000 cron 1 Oct	—	8.5	₹3,037.40
INNOVACAPInnova Captab Limited	6,700 cron 1 Oct	—	6.1	₹1,168.00
SPARCSun Pharma Advanced Research Company Limited	6,300 cron 1 Oct	—	4.7	₹194.15
SENORESSenores Pharmaceuticals Limited	6,200 cron 1 Oct	—	6.4	₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited	6,100 cron 1 Oct	—	3.4	₹209.40
ORCHPHARMAOrchid Pharma Limited	5,900 cron 1 Oct	—	4.6	₹990.00
FDCFDC Limited	5,500 cron 1 Oct	—	2.2	₹335.90
GUJTHEMGujarat Themis Biosyn Limited	5,000 cron 1 Oct	—	—	₹381.80
NOVARTINDNovartis India Limited	4,900 cron 1 Oct	—	—	₹1,965.00
RPGLIFERPG Life Sciences Limited	4,800 cron 1 Oct	—	8.0	₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited	4,400 cron 1 Oct	—	5.6	₹471.30
GUFICBIOGufic Biosciences Limited	4,200 cron 1 Oct	—	6.3	₹418.40
AARTIDRUGSAarti Drugs Limited	3,800 cron 1 Oct	—	2.5	₹421.00
UNICHEMLABUnichem Laboratories Limited	3,800 cron 1 Oct	—	1.4	₹535.05
KPLKwality Pharmaceuticals Limited	3,700 cron 1 Oct	—	—	₹3,564.40
SOLARASolara Active Pharma Sciences Limited	3,400 cron 1 Oct	—	2.7	₹714.85
INDSWFTLABInd-Swift Laboratories Limited	3,400 cron 1 Oct	—	2.5	₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited	2,700 cron 1 Oct	—	—	₹61.80
HIKALHikal Limited	2,700 cron 1 Oct	—	2.2	₹218.15
VENUSREMVenus Remedies Limited	2,400 cron 1 Oct	—	3.6	₹1,796.70
DCALDishman Carbogen Amcis Limited	2,400 cron 1 Oct	—	0.35	₹150.35
INDOCOIndoco Remedies Limited	2,300 cron 1 Oct	—	2.5	₹251.75
SAIPARENTSai Parenterals Limited	2,300 cron 1 Oct	—	4.7	₹523.65
SYNCOMFSyncom Formulations (India) Limited	2,300 cron 1 Oct	—	5.4	₹23.95
FREDUNFredun Pharmaceuticals Limited	2,200 cron 1 Oct	—	—	₹1,355.20
WINDLASWindlas Biotech Limited	2,200 cron 1 Oct	—	—	₹1,082.40
PANACEABIOPanacea Biotec Limited	2,200 cron 1 Oct	—	2.6	₹359.05
HESTERBIOHester Biosciences Limited	1,800 cron 1 Oct	—	4.9	₹2,126.80
NGLFINENGL Fine-Chem Limited	1,800 cron 1 Oct	—	5.5	₹2,924.00
AHCLAnlon Healthcare Limited	1,700 cron 1 Oct	—	6.8	₹32.85
FERMENTAFermenta Biotech Limited	1,600 cron 1 Oct	—	—	₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited	1,500 cron 1 Oct	—	5.5	₹231.75
AMRUTANJANAmrutanjan Health Care Limited	1,500 cron 1 Oct	—	4.0	₹513.20
KOPRANKopran Limited	1,400 cron 1 Oct	—	2.6	₹282.05
BPLPHARMABharat Parenterals Limited	1,200 cron 1 Oct	—	—	₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited	1,200 cron 1 Oct	—	1.5	₹582.05
BAJAJHCAREBajaj Healthcare Limited	1,100 cron 1 Oct	—	2.0	₹322.95
SIGACHISigachi Industries Limited	1,100 cron 1 Oct	—	2.0	₹28.35
THEMISMEDThemis Medicare Limited	1,000 cron 1 Oct	—	2.6	₹113.20
SGRLShree Ganesh Remedies Limited	890 cron 1 Oct	—	—	₹694.25
ANUHPHRAnuh Pharma Limited	860 cron 1 Oct	—	2.4	₹85.85
ZIMLABZim Laboratories Limited	740 cron 1 Oct	—	2.5	₹137.00
WANBURYWanbury Limited	690 cron 1 Oct	—	4.8	₹198.00
ALBERTDAVDAlbert David Limited	490 cron 1 Oct	—	1.3	₹856.70
MEDICAMEQMedicamen Biotech Limited	470 cron 17 Sept	—	1.7	₹346.30
HALEOSLABSHALEOS LABS LIMITED	450 cron 1 Oct	—	2.0	₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited	400 cron 1 Oct	—	—	₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	290 cron 1 Oct	—	2.0	₹103.85
NECLIFENectar Lifesciences Limited	200 cron 1 Oct	—	0.34	₹10.25
MEDICOMedico Remedies Limited	180 cron 1 Oct	—	2.4	₹21.85
BALPHARMABal Pharma Limited	170 cron 1 Oct	—	2.0	₹105.75
BROOKSBrooks Laboratories Limited	160 cron 1 Oct	—	1.3	₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited	150 cron 1 Oct	—	—	₹68.05
PARNAXLABParnax Lab Limited	130 cron 1 Oct	—	—	₹113.15
ALPAAlpa Laboratories Limited	120 cron 1 Oct	—	0.67	₹59.25
MAKERSLMakers Laboratories Limited	110 cron 1 Oct	—	—	₹183.50
SUNLOCSunil Healthcare Limited	72 cron 1 Oct	—	—	₹70.10
VINEETLABVineet Laboratories Limited	69 cron 1 Oct	—	1.5	₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited	48 cron 1 Oct	—	2.2	₹29.30
MANGALAMMangalam Drugs And Organics Limited	46 cron 1 Oct	—	0.45	₹29.15
MEDICAPQMedi Caps Limited	31 cron 17 Sept	—	—	₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED	12 cron 1 Oct	—	9.5	₹14.50
AMANTAAmanta Healthcare Limited	—	—	—	—
AMBALALSAAmbalal Sarabhai Enterprises Limited	—	—	—	—
BAFNAPHBafna Pharmaceuticals Limited	—	—	—	—
BLISSGVSBliss GVS Pharma Limited	—	—	—	—
KILITCHKilitch Drugs (India) Limited	—	—	—	—
LASALasa Supergenerics Limited	—	—	—	—
LYKALABSLyka Labs Limited	—	—	—	—
NATCAPSUQNatural Capsules Limited	—	—	—	—
VALIANTLABValiant Laboratories Limited	—	—	—	—
VIVIMEDLABVivimed Labs Limited	—	—	—	—

Shareholding

quarter to 30 Jun · 1.7% of the promoter holding pledged · NSE filings

Promoters hold 54.5%, foreign portfolio investors 14.5%, mutual funds 12.8% and insurance companies 7.0%, as filed for the quarter to 30 Jun.

54.5%14.5%12.8%

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file

Shareholding of SUNPHARMA by category over the last 5 quarters with the change against the previous quarter
Category	30 Jun	31 Mar	31 Dec	30 Sept	30 Jun
Promoters	54.480.00 pp	54.480.00 pp	54.480.00 pp	54.480.00 pp	54.48
Foreign portfolio investors	14.54▼ −1.40 pp	15.94▼ −0.18 pp	16.12▼ −0.43 pp	16.55▼ −0.71 pp	17.26
Mutual funds	12.84▲ +0.88 pp	11.96▼ −0.13 pp	12.09▼ −0.32 pp	12.41▼ −0.22 pp	12.63
Insurance companies	7.02▲ +0.19 pp	6.83▲ +0.26 pp	6.57▲ +0.61 pp	5.96▲ +0.87 pp	5.09
Banks and financial institutions	2.31▼ −0.01 pp	2.32▲ +0.15 pp	2.17▲ +0.31 pp	1.86▲ +0.09 pp	1.77
Individual investors	5.77▲ +0.18 pp	5.59▼ −0.09 pp	5.68▼ −0.14 pp	5.82▲ +0.20 pp	5.62
Bodies corporate	2.05▲ +0.03 pp	2.02▼ −0.01 pp	2.03▼ −0.02 pp	2.05▼ −0.02 pp	2.07
Others	0.99▲ +0.13 pp	0.860.00 pp	0.86▼ −0.01 pp	0.87▼ −0.21 pp	1.08

Corporate actions

NSE and BSE records

Nothing upcoming on record; the last was a dividend of ₹5.00 a share, ex-date 7 Jul 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios

Corporate actions of SUNPHARMA, upcoming first, then the most recent
Ex-date	Action	Amount or ratio	Record date	Source
recent
7 Jul 2026	dividend	₹5.00	7 Jul 2026	BSE
5 Feb 2026	dividend	₹11.00	5 Feb 2026	BSE
7 Jul 2025	dividend	₹5.50	7 Jul 2025	BSE
6 Feb 2025	dividend	₹10.50	6 Feb 2025	BSE
12 Jul 2024	dividend	₹5.00	12 Jul 2024	BSE
9 Feb 2024	dividend	₹8.50	9 Feb 2024	BSE

Calendaras notified to the exchange

Next results: —no board meeting notified yet
Dividends in 365 days: ₹32.00a share · ex-dates inside the year
Last dividend: ₹5.00ex-date 7 Jul 2026

Price history

272 sessions on record · to 1 Oct · NSE end of day

SUNPHARMA is −6.8% over 20 sessions against Nifty's −6.2%, 12% below its 52-week high, realised volatility 17% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions

Returns of the stock and Nifty 50 over six windows, longest first
Window	From ₹	SUNPHARMA %	Nifty 50 %	Difference pp
250 sessionssince 26 Sept	₹1,586.64	▲ +14%	▼ −9.1%	+23
120 sessionssince 9 Apr	₹1,717.04	▲ +4.9%	▼ −5.7%	+11
60 sessionssince 8 Jul	₹1,888.24	▼ −4.6%	▼ −6.1%	+1.5
20 sessionssince 2 Sept	₹1,931.78	▼ −6.8%	▼ −6.2%	−0.53
5 sessionssince 24 Sept	₹1,849.84	▼ −2.6%	▼ −2.8%	+0.14
1 sessionsince 30 Sept	₹1,816.62	▼ −0.86%	▼ −0.88%	+0.02

Averages of the closeclose against each average

5-session average: ₹1,834.56close −1.8% from it
20-session average: ₹1,857.90close −3.1% from it
50-session average: ₹1,906.29close −5.5% from it
200-session average: ₹1,807.70close −0.37% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: ₹311.7% of the close
Average day's range, 20: ₹281.6% of the close
Volume against 20 sessions: 1.51×23 L vs 16 L average

Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell

Realised volatility, 20: 17%≈ ±1.1% a session · moved more than that on 7 of 20
Realised volatility, 60: 18%≈ ±1.1% a session · moved more than that on 15 of 60
Realised volatility, 250: 19%≈ ±1.2% a session · moved more than that on 61 of 250
Beta to Nifty, 60: 0.33moved with Nifty on 36 of 60 sessions
Beta to Nifty, 250: 0.47moved with Nifty on 151 of 250 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 6 up · 14 downof 20
Last 60 sessions: 27 up · 33 downof 60
Last 250 sessions: 132 up · 118 downof 250
Best session, 250: ▲ +7.0%27 Apr
Worst session, 250: ▼ −3.7%20 Jan

Sun Pharmaceutical Industries Limited is in 19 NSE indices

all 19 indices

22 bulletins on SUNPHARMA

latest 26 Jul 2026

Beats in the coverage

Often mentioned with

July 2026

26 Jul Sun Pharma's $9.4 billion Organon acquisition approvedSun Pharmaceutical Industries secured Organon shareholders' approval for its $9.4 billion acquisition, which focuses on women's health and biosimilars. This deal, pending regulatory approvals, would be the largest in Sun Pharma's history.High 24 Jul Organon shareholders approve Sun Pharma's $11.75 billion acquisitionOrganon shareholders approved Sun Pharma's acquisition proposal valued at $11.75 billion, marking a key milestone. The deal is subject to customary closing conditions and regulatory approvals before Organon becomes a wholly owned subsidiary of Sun Pharma.High 15 Jul Sun Pharma Q1 earnings call set for July 31 after profit surgeSun Pharmaceutical Industries will hold its Q1 FY27 earnings call on 31 July 2026, following a 34% profit increase in Q4, with net profit at ₹2,654 cr. Investors await updates on regulatory status and specialty drug launches.Medium 11 Jul Sun Pharma to review Q1 FY27 results on July 31Sun Pharmaceutical Industries will release its Q1 FY27 financial results on 31 July 2026, focusing on specialty product growth contributing 16-18% to global sales. The announcement is significant for the healthcare sector's performance amid regulatory compliance issues.Medium

May 2026

25 May Sun Pharma Q4 net profit rises 26.2% to ₹27,140 millionSun Pharmaceutical reported Q4 FY26 net profit of ₹27,140 million, a 26.2% increase YoY. Consolidated sales rose to ₹145,598 million, driven by a 20.1% growth in Global Innovative Medicines sales, contributing significantly to overall revenue.High 23 May Sun Pharma Q4 profit rises 26% YoY to ₹2,714 croreSun Pharmaceuticals reported a consolidated net profit of ₹2,714 crore for Q4, a 26% YoY increase. Revenue rose 13% to ₹14,612 crore, while the board approved a ₹5 per share dividend, subject to AGM approval.Medium 20 May Sensex drops 600 points amid geopolitical uncertaintyBenchmark indices opened lower with the BSE Sensex down 389.19 points to 74,811.66 and Nifty50 falling 107.90 points to 23,510.10. The decline is attributed to geopolitical uncertainty and rising US bond yields, impacting market sentiment.High 20 May Indian firms announce $20.5 billion investment in USIndian firms announced a combined $20.5 billion investment in the U.S. at the SelectUSA Investment Summit 2026, with over $19.1 billion allocated to pharmaceuticals. Sun Pharmaceutical's planned $11.75 billion acquisition of Organon & Co. is a key highlight.High 19 May Indian firms commit $20.5 billion in US investmentsIndian firms announced $20.5 billion in investments across the US, focusing on pharmaceuticals, technology, and engineering. Sun Pharmaceutical's planned $11.75 billion acquisition of Organon & Co. highlights the significant commitment to job creation and supply chain enhancement.High 8 May Indian firms commit $20.5 billion to US investmentsIndian firms pledged $20.5 billion in the US, with the pharmaceutical sector leading at $19.1 billion. Sun Pharmaceutical's $11.75 billion acquisition of Organon & Co. highlights the sector's growth potential and may boost market sentiment.High 8 May Sun Pharma to acquire Organon for $11.75 billionSun Pharmaceutical Industries announced a definitive agreement to acquire Organon & Company for $11.75 billion in an all-cash deal at $14 per share. The transaction is expected to close in six to nine months, enhancing Sun Pharma's market position.High 7 May Sun Pharma to acquire Organon for $11.75 billionSun Pharmaceutical Industries announced an $11.75 billion acquisition of Organon & Company at $14 per share. The deal is expected to close in six to nine months, enhancing Sun Pharma's market presence and product portfolio.High 4 May Pharma Q4 outlook mixed with steady hospitals and generics pressurePharmaceuticals sector outlook for Q4 is mixed, with hospitals showing steady growth while generics face challenges from Revlimid sales decline. Lupin and Divi's are expected to perform well, while Sun Pharma benefits from strong domestic and international momentum.Medium 2 May Crude oil above $120 weighs on Indian equitiesIndian stock indices Sensex and Nifty fell nearly 1% as crude oil prices surpassed $120, influenced by weak global trends and foreign fund outflows of ₹2,468.42 cr. The Sensex closed at 76,913.50, down 582.86 points, while Nifty ended at 23,997.55, down 180.10 points.High

April 2026

29 Apr Sun Pharma plans $11.75 billion acquisition of OrganonSun Pharmaceutical Industries is acquiring Organon & Co. for $11.75 billion, supported by legal firms including AZB & Partners and Cyril Amarchand Mangaldas. This strategic move may strengthen Sun Pharma's position in the pharmaceutical market.High

February 2026

2 Feb Sun Pharma Q3 results show 16% profit growth and 1,100% dividendSun Pharma reported Q3 net profit of ₹3,381 cr, up 16% YoY, with revenue at ₹15,521 cr. The company declared an interim dividend of ₹11 per share, and shares increased 4% today, reflecting positive market sentiment.High 1 Feb Sun Pharma shares rise after strong Q3 earnings reportSun Pharmaceutical Industries reported a 16% rise in Q3 net profit to ₹3,369 cr, with total revenue increasing to ₹15,520 cr. The stock surged nearly 4% post-earnings, reflecting positive market sentiment.High 1 Feb Sun Pharma Q3 results show strong US sales performanceSun Pharmaceutical Industries Ltd reported Q3 net profit of ₹3,368.8 crore, a 16% YoY increase, with US sales at $477 million. Revenue rose 13.5% to ₹15,520.5 crore, surpassing estimates and indicating strong operational performance.High

January 2026

27 Jan Sun Pharma and Cipla recall products in US marketSun Pharma and Cipla are recalling products from the US market due to manufacturing issues. Sun Pharma is recalling 24,624 bottles of Fluocinolone Acetonide Topical Solution for failing impurity standards, classified as a Class III recall by the USFDA.Medium 27 Jan Sun Pharma and Cipla recall products in US marketSun Pharma and Cipla have recalled products in the US due to manufacturing issues. Sun Pharma is recalling 24,624 bottles of Fluocinolone Acetonide Topical Solution, classified as a Class III recall by the USFDA, indicating no expected health risks.Medium

December 2025

4 Dec Sun Pharma shares rise on ₹3,000 crore project approvalHigh 3 Dec Sun Pharma shares rise on ₹3,000 Cr capex announcementHigh

About Sun Pharmaceutical Industries Limited

exchange masters as of 18 Sept 2026 · classification by BSE

Company: Sun Pharmaceutical Industries Limited
Exchange: NSE · BSE 524715, group A
Listed on NSE: 8 Feb 1995
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index: BSE SENSEX
Face value: ₹1 a share
ISIN: INE044A01036
Sessions on record: 272
Price source: NSE UDiFF bhavcopy · end of day · delayed
Filings: NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed: 1 Oct, 11:57 pm IST
Bulletins: 22 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.